Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Federica Martorana(University of Catania), Grazia Arpino(University of Naples Federico II), Giacomo Barchiesi(Sapienza University of Rome), G. Zucchini(Ferro (United States)), Margherita Muratore(Agostino Gemelli University Polyclinic), Mario Giuliano(Regione Campania), Caterina Fontanella, Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Puglisi(University of Udine)
Cited by 40
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830